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Summary Recombinant Interleukin 4 was administered by subcutaneous injection at daily doses of 0.5, 1.0 or
5.0 lag kg-' to nine patients as part of a Phase I Dose Toxicity Study. Dose limiting toxicity was reached at
5 Ag kg-' day-'. Symptoms of toxicity included fatigue, 'flu like symptoms and elevated liver enzymes. Modest
but significant elevations of neutrophil and platelet counts occurred. No clear evidence of antitumour effects
emerged although pain in metastatic lymph nodes and a small fall in myeloma paraprotein levels during
dosing were observed. In vitro and murine in vivo studies indicate that patients with lymphoproliferative
disease should be selected for Phase II trials.
The production of growth factors and other cytokines by
recombinant DNA technology has facilitated assessment of
their in vivo therapeutic potential. Alpha Interferon has been
used effectively in the treatment of hairy cell leukaemia and
maintenance regimens for myeloma, while IL-2 immuno-
therapy has been used as an alternative to chemotherapy in
advanced stages of melanoma or renal cell carcinoma. Gran-
ulocyte and Granulocyte-Macrophage Colony Stimulating
Factor have recen'tly been shown to be of great promise in
ameliorating neutropenia associated with intensive chemo-
therapy. This paper reports the results of a Phase I dose
toxicity clinical trial of Interleukin 4 (IL-4) prior to determin-
ing potential anti-neoplastic properties in patients with malig-
nant disease.
IL-4 was first described in 1982 when its role as a distinct
B cell growth factor was recognised (Howard, 1982). It is
produced mainly by CD4 helper T lymphocytes and exhibits
a wide range of effects as an immunoregulatory lymphokine
and as a haemopoietic growth factor (Paul, 1991).
During the maturation of early B cells, IL-4 has been
shown to induce surface IgM expression and inhibit expres-
sion of the primitive B cell marker, CD5 (Hofman et al.,
1988; Defrance et al., 1989). IL-4 stimulates B cell prolifera-
tion in vitro and upregulates CD23, the low affinity IgE
receptor, which when secreted can act as a mitogen for B
cells (Gordon et al., 1988). It can also upregulate MHC class
II antigens (Noelle et al., 1984) and stimulate or inhibit
immunoglobulin production and isotype switching to favour
IgE production (Snapper et al., 1988).
In addition to its effects on B cell differentiation and
development, IL-4 can influence T cell viability and act as a
proliferative stimulus to preactivated T cells (Hu Li et al.,
1987). IL-4 also stimulates the differentiation of antigen
specific cytotoxic T lymphocytes (Horohow et al., 1988) but,
in human studies, does not induce lymphokine activated
killer (LAK) cell activity. Indeed, IL-4 may stimulate or
inhibit Interleukin 2 (IL-2) induced LAK activity although
inhibition can in part be overcome by gamma interferon
(Han et al., 1988; Spits et al., 1988; Widmer et al., 1987).
IL-4 has pleiotropic effects on various other haemopoietic
cells. Combinations of IL-4 with IL-3, G-CSF, erythro-
poietin, GM-CSF or M-CSF may be stimulatory or inhibi-
tory for myeloid progenitor cells (Jansen et al., 1989; Favre
et al., 1990; Broxmeyer et al., 1988).
From these data, it is apparent that IL-4 affects a broad
spectrum of cells and it is not surprising that the IL-4
receptor (IL-4R) is expressed by cell lines of several lineages,
including lymphoid, myeloid, fibroblast, endothelial and
epithelial (Cabrillat et al., 1987; Park et al., 1987).
The receptor is a single high affinity glycoprotein and is
maximally upregulated by IL-4 (Zuber et al., 1990).
While the precise physiological functions of IL-4 still
remain to be determined, it has emerged that IL-4 has potent
anti-tumour effects. These effects have been demonstrated
using transplantable malignant cell lines in murine experi-
ments. The tumour cell lines used were characteristically
poorly immunogenic and rapidly lethal when injected sub-
cutaneously into mice (Tepper et al., 1989). Transfection of
the IL-4 gene into these cells and subsequent expression of
IL-4 did not influence their in vitro growth characteristics,
but prevented in vivo growth. The anti-tumour effects exerted
by IL-4 were localised to the immediate vicinity of the
tumour which was heavily infiltrated with neutrophils, eosi-
nophils and macrophages.
Contralateral non-transfected cells, injected subcutaneously
into mice carrying IL-4 transfected tumour cells were not
rejected by the mice and showed little or no evidence of
infiltration with granulocytes and macrophages. Perilymphatic
injection of low doses of IL-4 around lymph nodes draining
nontransfected tumours resulted in suppression of tumour
development (Bosco et al., 1990) while contralateral simul-
taneous injection of tumour cells without local IL-4 led to
unrestrained proliferation. Mice exposed to tumour and IL-4
were able to reject further challenges with tumour cell alone.
Adoptive passive transfer experiments using sublethally irrad-
iated mice suggested that this memory effect was mediated by
CD4- T lymphocytes. The anti-tumour effects of IL-4 do not
seem to be confined to experimentally induced tumours since
growth inhibition in response to IL-4 has been demonstrated
in 56% of freshly isolated specimens of human lymphoid
malignancies (Taylor et al., 1990).
The immunomodulatory effects of IL-4 taken in conjunc-
tion with the demonstrated anti-tumour effects in vitro and in
vivo, have encouraged the proposal that IL-4 may be of use
in the treatment of malignant disease. A Phase I trial was
undertaken to evaluate the toxicity and biological effects of
IL-4 given at increasing dosage for prolonged periods using
the subcutaneous route.
Materials and methods
Study design
Non glycosylated recombinant human IL-4 (molecular weight
14,000 Da, Schering-Plough Research, Kenilworth, New
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Jersey) was supplied in vials containing 75 or 400 pg. Each
vial was reconstituted in 1 ml of sterile distilled water. The
trial was approved by the local ethical committee. The design
of the trial was for each patient to receive a single sub-
cutaneous injection on days 1 (cycle 1) and 8-17 (cycle 2).
Those patients who tolerated the drug then went on to
receive daily injections on days 29-57 (cycle 3). No IL-4 was
given during intervening days. The aim of the trial was for
three patients to be entered at each of the following dose
levels: 0.5, 1.0, 5.0, 10, 25 jgkg-'day-'. There was no dose
escalation within the same patient's regimen, and the aim of
the study was to establish the dose at which toxicity in any
system (WHO grade 3/4) occurred in two out of three
patients and was the main limiting factor preventing dose
escalation.
Patients
Patients over 18 years of age who had given informed con-
sent were entered into the study if they had a malignancy
confirmed by histological examination and were unresponsive
to conventional therapy. All patients had normal renal func-
tion (urea less than 7.5 mmol 1', creatinine less than 0.12
mmol 1'), and adequate bone marrow function (white blood
cells more than 3 x 1091' and platelets greater than 100 x
lO9 1'). WHO performance status (Miller et al., 1981) was 0,
1 or 2 and each patient was at least 2 weeks beyond the toxic
effects of any prior therapy. Patients were excluded from
entry to the trial if they had received any lymphokine within
the previous month or any exposure to IL-4. Diabetes melli-
tus or other condition likely to decompensate under stress,
major surgery in the preceding 14 days, acute leukaemia,
infection, pregnancy, active gastrointestinal bleeding or intra-
cerebral metastases were further criteria for exclusion.
Clinical and laboratory monitoring
Patients attending hospital three times weekly throughout the
trial. Regular haematological and biochemical investigations
were performed before and during treatment with IL-4.
These included differential blood counts, T-cell helper/sup-
pressor ratios, measurement of prothrombin and partial
thromboplastin times, biochemistry screen (including liver
enzymes, glucose and uric acid), serum immunoglobulins,
cholesterol, triglycerides and iron, and urinalysis. Clinical
monitoring took the form ofphysical examination with parti-
cular attention to tumour assessment, weight, blood pressure,
radial pulse and oral temperature. Periodic electrocardio-
grams and chest radiograms were performed. Skin testing
(multi-test kits, Institut Merieux) was performed pretreat-
ment, and on days 29 and 64 using as challenging antigens,
tuberculin, tetanus, glycerin, proteus, candida and streptococ-
cus A. The calculated average diameters of all positive reac-
tions were summated to give a score for each test.
Clonogenic and IL-4 receptor assays
Bone marrow aspirates were taken under local anaesthetic
from the posterior superior iliac crest for morphological
assessment and in vitro assays pre-treatment and on days 17,
29 and 57.
Twenty ml of heparinised venous blood were collected on
the same days. Bone marrow cells for in vitro manipulation
were collected in Iscove's medium (Gibco) with 50 units of
preservative free heparin (CP Pharmaceuticals Ltd). Three
aliquots of this suspension were prepared and clonal assays
performed as described previously (Testa, 1985) with minor
modifications. Briefly, red cells were removed by sedimenta-
tion in 0.1% methylcellulose over 30 min at room tempera-
ture. The stromal cell population (CFU-F, Colony Forming
unit - fibroblast) was assayed by suspending cells at 1 x 105
ml-' in 5 ml of 15% horse serum (Medical Veterinary Supp-
lies) in Iscove's medium in flasks (Falcon T25) gassed with
5% CO2 and incubating for 10 days at 37°C. The flasks were
washed with phosphate buffered saline and the adherent cells
fixed in methanol and stained with Crystal Violet. Colonies
containing more than 50 fibroblasts were scored. The Ficoll
(Flow) separated mononuclear fraction of the second aliquot
of bone marrow cells was plated at I05 cellsml-' in 1.2%
methylcellulose, 10% conditioned medium from the 5637
bladder carcinoma cell line (as a source of colony stimulating
factors, Myers et al., 1984), 2 units of recombinant erythro-
poietin (Terry Fox Lab), 1% bovine serum albumin (Sigma)
and 30% foetal calf serum (Flow Laboratories) in Iscove's
medium. Colonies of more than 50 cells were scored as
BFU-E (Burst forming unit - erythroid), GM-CFC (Granu-
locyte macrophage-colony forming cells) and Mix-CFC (Mix-
ed lineage - colony forming cells).
The remaining fraction of bone marrow cells was assayed
for IL-4R using a method previously described (Heyworth et
al., 1991). Briefly, aliquots (200pl) containing 3 x 106 cells
and 125I-labelled IL-4 Specific Activity 1000-1030 Cimmol-'
(gift from Amersham International) at final concentrations of
5-300 pM, were incubated at 26°C for 2 h in the presence or
absence of a 30-fold excess of unlabelled IL-4 (gift from
Amersham International)
Scatchard analysis was performed to check for the pre-
sence of high affinity IL-4R. MLA-144 (Rabin et al., 1981) a
cell line known to express high numbers of IL-4R was grown
in 10% foetal calf serum in RPMI-1640 (Gibco) and used to
confirm the specificity of the 1251I IL-4.
Immunological assays
Venous blood taken pre-treatment and on days 15, 29 and 57
was used to assess the immunological responses to IL-4.
Peripheral blood mononuclear cells (PBMC) were isolated
from 40 ml of heparinised blood by lymphocyte separation
medium (Flow Laboratories).
Fresh PBMC were effectors in a 4 h 5'Cr release assay to
assess the level of NK and in vivo LAK activity against
K562, an erythroleukaemia cell line (NK sensitive and LAK
sensitive) and Daudi, a Burkitt's lymphoma cell line (NK
resistant and LAK sensitive). LAK cells generated in vitro
were subjected to a similar assay to assess the ability of LAK
precursors to become activated. PBMC were assayed in trip-
licate at effector to target cell ratios of between 40:1 and 10:1
with 5 x 103 5'Cr labelled target cells per well. Cytotoxicity
was calcualted according to the formula:
% cytotoxct. . 51Cr release test - spontaneous 51Cr release /cytotoxicity maximum5'Cr release -spontaneous 51Cr release
Spontaneous release was obtained by incubating target
cells with medium only and maximum release by incubation
of target cells with Triton X-100. A more detailed description
of this method is given by Ghosh et al. (1989).
LAK cells were generated by incubating 2 x 106 ml1
PBMC with 200 I ml1 IL-2 (Cetus, Emeryville CA) in six
well plates for 4 days. Cells were then harvested and washed
twice before assessment of LAK activity.
PBMC were assessed for their ability to proliferate in the
presence of mitogens over the trial period. Three concentra-
tions of each mitogen were placed in 96 well plates in trip-
licate (100 lwell') to which 100il of PBMC at 2 x 106
ml-1 were added. Following an incubation at 37°C for 3 days
the cells received 1 gACi of 3H-thymidine 4 h prior to harvest-
ing by a cell harvester (Dynatech) onto glass fibre paper.
Radioactive uptake was assessed by scintillation counting
and a stimulation index (SI) calculated by the formula:
SI _ Mean of test samples
Mean of control samples
Controls consisted of nine wells of cells with no mitogen.
The PBMC were assessed against purified Phytohaemaglu-
tinin (PHA, Wellcome Diagnostics) at 1, 0.1 and 0.001 jig
ml-1, Pokeweed mitogen (PWM, Sigma) at 1, 0.1 and 0.01 tLg
ml-', Formalinised staphylococcus aureus strain cowan 1
(SAC, Sigma) at 0.1, 0.01 and 0.001% v/v, IL-2 at 200, 40
and 10 iml-' and Interleukin-4 IL-4 (Immunex Corpora-
tion); at 2000, 1000 and 200tml'1.206 M.H. GILLEECE et al.
The phenotype of patients lymphocytes was evaluated by
FACS on a Coulter Flow Cytometer. Monoclonal antibodies
CD3, CD4, CD8 and CD20 were obtained from Coulter
electronics and used in a direct fluorescence method. An
indirect immunofluorescence method was used to analyse
CD23 purchased from Becton-Dickinson, W6/32 (HLA class
1) purchased from Sera-Lab, HLADr purchased from Ortho
Diagnostics and CDW32 purchased from The Binding Site.
Statistical analysis
Changes in the differential blood count were assessed using
Repeated Measures Analysis of Variance using each dose
level as groups and days as repeated measure (BMDP
Routine 2V).
Results
Nine patients were entered into the trial, three each at dose
levels 0.5, 1, and 5pgkg-'day-'. Eight had solid tumours,
most originating in the gastrointestinal tract, and one had
multiple myeloma. Three had received previous chemother-
apy, one radiotherapy and five had had palliative surgery
(Table I). All patients completed cycle I and II of dosing and
five patients completed cycle III.
Two patients at the lowest level of dosing withdrew from
the trial because of disease progression and two patients at
5pgkg-1 were withdrawn at day 24 and day 32 because of
WHO grade III toxicity. The injection of IL-4 subcutan-
eously was well tolerated with no pain or reaction at the sites
of infection. Two patients learnt to give their own injections.
The remaining patients were given their injections by the
District Nurse at home. Generalised symptoms of toxicity,
such as anorexia, lethargy and 'flu-like symptoms occurred at
all dose levels, but subsided within 24 h of the end of each
cycle. Dose increments were associated with symptoms of
increasing severity and although toxicity at 0.5 ILg kg-' was
mild (WHO grade 0-1), one patient reported visual hallu-
cinations during cycle 3 of dosing. These resolved on chang-
ing the timing of the injections from morning to evening.
Grade 1-2 toxicity occurred at fg kg-' except when one
patient was inadvertently given twice his usual dose and
experienced severe arthralgia for 48 h. At 5 jig kg- ' two
patients, 8 and 9, were withdrawn because of grade 3 tox-
icity. Both were pyrexial after dosing and reported severe
arthralgia. Patient 8 developed hepatic encephalopathy, but
analysis of stored sera revealed him to have been infected
with hepatitis C at least 2 years before entry to the trial and
residual liver damage may have been a factor although his
liver function improved rapidly on stopping IL-4. Patient 9
experienced photophobia, pain in metastatic lymph nodes
and vomiting (Table II).
Five patients had liver disease (3, 4, 5, 7 and 8), and two
had bony disease (7 and 8) assumed to be secondary to their
malignancy. During IL-4 treatment there was elevation of
alkaline phosphatase (eight patients), gamma glutamyl trans-
ferase (six patients), alanine transaminase (four patients),
aspartate transaminase (three patients) and lactate dehydro-
genase (two patients), but no significant changes in serum
cholesterol or triglyceride levels. Isoenzyme studies in patient
9 confirmed that the elevated alkaline phosphatase was of
liver origin. there were no consistent changs in serum
immunoglobulins. The rapidly rising myeloma paraprotein in
patient 8 with multiple myeloma fell by 15% after 7 days of
IL-4 (Table III). However, he was withdrawn from the trial
on day 24 because of toxicity, and his paraprotein subse-
quently increased.
All five patients with pre-existing liver disease showed
elevation ofprothrombin time by up to 4 s more than control
during IL-4 dosing, although the prothrombin time fell to
normal in two of these patients when IL-4 was stopped. Two
patients without evidence of liver metastases had prolonga-
tion of the prothrombin time by 2 s. One of these patients
was withdrawn due to disease progression while the proth-
rombin time fell to normal in the other when IL-4 was
stopped. The partial thromboplastin time was prolonged by
up to 10s longer than control in those patients with liver
metastases and transiently by 3 s in one patient without liver
metastases. Despite these alterations in clotting times, while
one patient had a haematemesis related to his malignancy, no
other patients had major episodes of bleeding. Faecal occult
blood specimens were positive at some stage of the trial for
five to eight patients but these results bore no obvious rela-
tionship out of dosing and in four patients could have been
disease related. Significantly, microscopic haematuria was
absent in all patients.
There were modest but statistically significant elevations in
neutrophils (P<0.00005) and platelets (P=0.0024) during
cycle three of dosing. This rise was most evident at day 36.
In patient 7 at 5 1tg kg-' the rise in neutrophils and platelets
was substantially higher than in patients at 0.5 or 1.0 yg kg-'
(Figures 1 and 2). There were no significant changes in
lymphocyte, eosinophil, basophil or monocyte levels and
fluctuations in haemoglobin were unrelated to IL-4 dosing.
Bone marrow aspirates, sampled pretreatment and on days
Table I Patients entered on Phase I trial of subcutaneous IL-4
Patient IL-4
no. ggkg-' Sex Age Diagnosis Previous treatmentfor malignancy
1 0.5 F 51 Adenocarcinoma Gastroenterostomy and choledochojejunostomy
pancreas
2 0.5 M 39 Anaplastic carcinoma Six courses: Vincristine 2 mg; Adriamycin 75 mg;
oesophagus Cyclophosphamide 750 mg
3 0.5 M 56 Adenocarcinoma Nil
4 1 M 49 Adenocarcinoma Whipples procedure
pancreas
5 1 M 55 Adenocarcinoma Right hemicolectomy
caecum 5 Fluorouracil 2.5 mg weekly for
aIFN 3 megaunits x 3/wk 4 months
6 1 M 57 Squamous cell Radiotherapy right upper lobe
carcinoma bronchus
7 5 M 47 Squamous cell Oesophagectomy
carcinoma oesophagus
8 5 M 64 Myeloma Melphalan and Prednisolone; cyclophosphamide;
dexamethasone; vincristine; adriamycin, aIFN
9 5 F 53 Squamous cell Oesophagectomy
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Table II Symptoms of toxicity following IL-4 injections
Patient Dose Days on Reasonfor WHO grade of
no. mgkg-' trial withdrawal Toxicity toxicity
1 0.5 54 Disease Papular rash over forearms, days 8-10 1
progression Shivering
Headache, 8 h after injection, resolved overnight 1
2 0.5 85 - Shivering 2 h after dosing,
Lethargy J days 11-17, 29-57 1
Sweating for 1 h
Visual hallucinations after morning doses during 3rd phase of dos- -
ing, stopped when doses changed to evening admin.
3 0.5 25 Disease Lethargy during dosing period I
progression
4 1 85 - Back pain 12 h after dosing, 2
Shivering J days 12-19 for 15 min
Anorexia during dosing period
5 1 85 - Shivering - 21 h after dosing, days 8-17 29-57, variable duration
Day 13: Twice usual dose given in error: headache, back pain and 3
shoulder pain
Anorexia and lethargy during dosing period 1
6 1 85 - Lethargy after first dose 1
7 5 85 - Lethargy after first dose 1
8 5 24 Toxicity Epistaxis, day 1
Arthralgia day 3, day 12 3
Temperature 37.5, day 10-12 1
Confusion, paranoia and encephalopathy, days 17-20
9 5 32 Toxicity Headache, arthralgia 3
Photophobia, shivering
Nausea 2
Temperature 37.5, Pain in affected lymph nodes, days 8-18, 29-31 1
17, 29 and 57, showed no evidence of malignant infiltration
except in patient 8 who had multiple myeloma. No significant
morphological changes were observed during the period of
the trial. Bone marrow cells were assessed for the presence of
clonogenic haemopoietic and stromal precursors. No consis-
tent trends were observed at any dose levels (colony numbers
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Figure 1 Changes to neutrophil counts in peripheral blood
associated with IL-4 dosing. Patient identities indicated in
brackets on each graph.
range: 0-98 GM-CFC, 0-61 BFU-E, 0-3 CFU-MIX per
2.5 x 104 cells and 0-65 CFU-F per 5 x 105 cells).
Bone marrow mononuclear cells from patients 5, 6, 8 and
9 were assayed for IL-4 receptors pretreatment and on days
17 and 57 but there were no detectable levels prior to or
following treatment. In contrast, assays of the MLA-144 cell
line used as positive control consistently indicated receptor
levels of 290-448 per cell and KD 45-109 pM.
Changes in immune function induced by IL-4 were assess-
ed indirectly but IL-4 did not enhance delayed hypersensiti-
vity reactions as judged by skin testing with defined allergens
since in all patients the skin test score fell or remained at
zero. The in vitro cytotoxicity of PBMC was assayed against
the cultured tumour targets K562 (NK sensitive) and Daudi
(NK resistant, LAK sensitive) in all patients. Pretreatment
cytotoxicity against K562 varied from 2-39% with five
patients showing positive cytotoxicity (above 10%). In
patients 4 and 6 cytotoxicity towards K562 increased above
pretreatment values on day 28 from 22 to 33% and 11 to
42% respectively, but by day 56, values had decreased to 3
and 6%. In all other patients cytotoxicity towards K562
decreased or remained the same over the treatment period.
There were no significant changes in cytotoxicity towards
Daudi cells during the treatment period. In all nine patients
examined, the PBMC contained LAK cell precursors esti-
mated by induction of cytotoxicity against the NK resistant,
LAK sensitive target Daudi by incubation with IL-2 in vitro
for 4 days. There were no significant quantitative changes
observed of in vitro LAK cell activity in serial blood samples
taken throughout the rIL-4 treatment and values were com-
parable to normal controls, i.e. 60-80%.
To evaluate whether or not in vivo IL-4 administration has
any effect on proliferative responses, PBMC obtained at
various times pre and post treatment were incubated with
different doses of PHA, PWM, SAC, IL-2 and IL-4. Two of
the three patients at 0.5 ytgkg-' had 2-fold increased pro-
liferative response to PWM on day 15 but no significant
increase in response to PHA. Of the three patients who
received 1 jg kg-' IL-4, one had a 3-fold increase in pro-
liferative response to PHA on days 15 and two had 2-4-fold
increased proliferative response to PWM but these decreased
at the end of the treatment period. Patients at 5fig kg-' had
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but in no other patients were changes observed. The percen-
tage positive fraction of CD23 antigen bound to PBMC fell
in patient 8 from 14 to 4 following the first two cycles of
IL-4 dosing (Table III). The patient was withdrawn from the
trial on day 24 and the percentage positive fraction then rose
from 10 on day 24 to 25 on day 30. There were no increases
in percentages of Class II MHC positive lymphocytes over
the treatment period.
Discussion
600 -
e)
0-
0)
400 -
200'
0
600
400*
200-
(1.0)
,"s s-- ---- "vv ,--(5)
(4)
200- ___ _~___ - - - - (6)
I- I _- I _1 I_
(5.0)
(7)
%(9)
-(8)
0 14 28 42 56 70 84
Days
Figure 2 Changes to platelet counts in peripheral blood
associated with IL-4 dosing. Patient identities indicated in
brackets on each graph.
no increased proliferative response to PWM or PHA. Res-
ponses to SAC were minimal. Six patients, 2 at 0.5 yg kg-1, 3
at 1.0 iLg kg-', and one patient at 5iLgkg-' had a slightly
increased proliferative response to IL-2 on day 15 (2.5-7-
fold) and in four of these patients the increases were sus-
tained at the end of the 3rd treatment cycle. Two patients at
5jigkg-' had an increased proliferative response to IL-4 at
the end of the treatment cycle.
Cell surface markers were analysed on serial samples from
nine patients on IL-4 treatment. There were no significant
changes in the percentage of CD3 (pan T) positive cells over
the treatment period, although in one patient it decreased
from 62% to 53% on day 56. There were slight fluctuations
in the percentages of CD4 (T helper) and CD8 (T suppressor
cytotoxic) positive cells, but no consistent pattern of change
was observed. Slight decreases in the percentage of CD20
(pan B) positive lymphocytes were observed on days 15 in 5
patients. Patient 8 showed the greatest decrease from 19% to
8% on day 15. This patient was withdrawn because of tox-
icity on day 24 and CD20 positive lymphocytes subsequently
increased to 32% on day 56 coinciding with a terminal
relapse of myeloma disease. In other patients, percentages of
CD20 positive cells were not significantly different at the end
of the treatment period. SIgM positive cells increased in
patient 8 from 4% to 20% coinciding with myeloma relapse,
Table III Changes in serum IgG monoclone and % positive CD23
expressing peripheral blood mononuclear cells in patient 8. IL-4 was
given on days 1 and 8-17
Day IgG monoclone gV' CD23%
-23 68 -
0 80 14
8 60 -
15 58 4
24 64 10
30 80 25
Nine patients entered this trial to assess the toxicity of sub-
cutaneous injections of IL-4. All patients experienced some
toxicity but at 0.5 and 1pgkg-' day'- these symptoms were
mild and did not interfere with dosing. Two of the three
patients treated at 5 pgkg- Iday-' developed WHO grade III
toxicity. This suggests that the maximum tolerated dose is
between 1 and 5 pgkg- dayl'.
The side effects of lethargy, headache, 'flu-like symptoms
and arthralgia are similar to the spectrum ofeffects seen with
administration of a variety of other recombinant cytokines.
Patient 5 who had previously had Alpha Interferon described
almost identical side effects.
Elevation of liver enzymes and prolongation of prothrom-
bin time were provoked by IL-4 dosing and suggested that
IL-4 caused transient hepatic damage, particularly in patients
with pre-existing liver disease. These elevations were asymp-
tomatic except in patient 8 who had evidence of previous
Hepatitis C infection and in this patient IL-4 may have
exacerbated virus induced liver damage. Since Alpha Inter-
feron has been shown to control disease activity in Hepatitis
C induced chronic liver disease this is an interesting observa-
tion, particularly as IL-4 and Interferon frequently have
antagonistic actions in vitro (Davis et al., 1989).
In this Phase I trial no clear evidence of tumour response
was observed although patient 8 who had myeloma, showed
a fall in paraprotein and percentage positive membrane
bound CD23 coincident with IL-4 treatment. Both rose on
withdrawal of IL-4 treatment, when the patient's disease
progressed. CD23 has a dual role as a low affinity IgE
receptor and as a marker of B cell proliferation (Conrad,
1990; Cairns & Gordon, 1990). The membrane bound protein
undergoes autoproteolysis to form soluble CD23 (sCD23)
fragments which are capable of stimulating B cell prolifera-
tion. IL-4 upregulates membrane bound CD23 expression in
vitro and synergises with sCD23 in its mitogenic effects on B
cells. The fall in membrane bound CD23 in patient 8 is
therefore unexpected and may be a manifestation of the
abnormal lymphoproliferation occurring in this patient in
whom normal proliferative signals would be likely to be
misinterpreted or ignored. Since this fall in CD23 expression
was accompanied by a fall in paraprotein it is possible that
IL-4 achieved some beneficial effect. Such observationsjustify
inclusion of patients with myeloma or other lymphopro-
liferative diseases in phase II trials.
IL-4 had no significant effects on myeloid or fibroblast
clonogenic progenitor cells in the bone marrow. In view of
the available data which show both stimulatory and inhibi-
tory effects of IL-4 on these cells in vitro it may have been
the case that at the doses used in this trial fine regulation of
cell production in the haemopoietic system was able to
compensate for this stimulus and still provide a balanced
production of mature cells. The moderate rise in peripheral
neutrophil and platelet counts seen during the middle ofcycle
3 of dosing was not reflected in the progenitor assays at the
beginning and end of the cycle and this may be a reflection
of homeostatic mechanisms. This is supported by the fact
that there was no evidence of increase in IL-4-R levels des-
pite the widespread expression of this receptor. Again this
may have been due to the low doses used or to the hetero-
geneity in terms of lineage and varying maturity of the cell
population assayed.
LAK cell precursors were present in all patients as demon-
strated by in vitro induction of LAK cytotoxicity with IL-2.
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However, in vivo IL-4 administration did not have any
measurable effect on NK activity or induce LAK cell activity.
This observation is in agreement with in vitro studies (Kawa-
kami et al., 1989) on the effects of IL-4 alone on unstim-
ulated PBMC. In vitro and in vivo IL-2 primed cells can
however show increased cytotoxicity and proliferation when
combined with IL-4 in vitro (Treismann et al., 1990). It has
been shown that IL-4 can augment proliferation of lympho-
cytes in the presence ofmitogens or preactivated cells in vitro
(Spits et al., 1987). In our study, slight increases were
observed in the proliferative response to PWM and PHA on
dl5 midway through a treatment cycle which may indicate
activation of the patients lymphocytes in vivo. In vitro studies
have shown IL-4 to inhibit proliferation of lymphocytes
when used simultaneously with IL-2, but at the end of the
third treatment cycle no inhibition was observed in the pro-
liferative response to IL-2, and in four patients (2, 4, 5 and 6)
it was augmented compared to pretreatment values. These
observations on the augmentation of proliferative response
suggest that IL-4 has stimulatory effects on subsets of lym-
phocytes in vivo and that combination therapy using IL-2
and IL-4 may be of value.
Preliminary data on the use of IL-4 in other Phase I trials
have recently appeared. In one study of ten patients a max-
imum tolerated intravenous dose of 10fg kg-I was reached
(Mier et al., 1991). Reported toxicities including nausea,
vomiting, fatigue, anorexia, headache, dyspnoea, hyponatrae-
mia and prolonged PT or PTT. In only one patient were
hepatic enzymes elevated. Another study (Freimann et al.,
1991) of 27 patients achieved an intravenous dose of 160fg
m2 day-' (18 patients) and a subcutaneous dose of 5,ug
kg-' day-' (nine patients) without reaching a maximum
tolerated dose. Common toxicities were fever, sinus conges-
tion and headache.
Asymptomatic elevations in liver enzymes necessitating
dose reduction were predominantly a feature of subcutaneous
dosing. Pharmacokinetic data for intravenous or subcuta-
neous routes of administration are not yet available but may
explain the difference in hepatotoxicity.
We have observed 5pgkg-' day-' to be the limiting dose
given subcutaneously. While we have seen no clear tumour
responses, the transient fall in myeloma paraprotein during
IL-4 dosing noted in patient 8 may suggest some suscepti-
bility of this tumour to IL-4. Certainly this would be in line
with reports from Maher et al. (1990) or responses to IL-4 by
two patients with lymphoproliferative disease and the in vitro
work of Taylor et al. (1990). These reports indicate that
patients with lymphoproliferative disorders should be selected
for Phase II trials.
We are pleased to acknowledge the assistance given by Dr Pum-
phries, St Mary's Hospital, Manchester, N. Smith, Sr V. Goode, J.
Taylor, L. Watmough, E. Mercer, R. Swindell and J. Cartwright of
the Christie Hospital Trust and Cliff Spence of Amersham Interna-
tional.
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